---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-058332"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-05-11T13:01:36+00:00"
generated_at: "2026-05-11T18:21:10.954037+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# MetaVia DA-1726 late-breaking abstract accepted for EASL 2026 poster; Phase 1 data expected Q4

## Summary
- Abstract LB26-5204 on DA-1726 (GLP-1/glucagon dual agonist) accepted for poster at EASL Congress 2026 in Barcelona (May 27-30).
- Poster title: Safety, Tolerability, PK, PD of DA-1726 in higher-dose Phase 1 cohort with exploratory liver assessment.
- Phase 1 Part 3 titration study ongoing; optimizing higher dose levels and tolerability; data expected Q4 2026.
- Presenting author: Chris Fang, CMO; poster available on MetaVia website after presentation.

## SEC filing metadata
- accession: 0001104659-26-058332
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-05-11T13:01:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926058332/0001104659-26-058332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926058332/mtva-20260511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-058332
- JSON: https://secwatch.observer/filing/0001104659-26-058332.json
- Plain text: https://secwatch.observer/filing/0001104659-26-058332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.